Tags : Two

Biosimilars

EMA’s CHMP Recommends the Approval of Two Bevacizumab Biosimilars

Shots: The EMA’s CHMP has adopted the positive opinion recommending the approval of two biosimilar bevacizumab medicines, Alymsys and Oyavas for the treatment of carcinoma of the colon or rectum, breast cancer, NSCLC, RCC, epithelial ovarian, fallopian tube or primary peritoneal cancer, and carcinoma of the cervix Mabxience’s Alymsys and STADA’s Oyavas both show comparable […]Read More

Biosimilars Clinical Trials

Samsung Bioepis Reports Results of Renflexis (biosimilar, infliximab) from Two

Shots: The company reported results from two real-world studies of Renflexis (infliximab-abda) in patients with IBD registered in the US Veteran Affairs Healthcare System database. Data were presented at ACG 2020 One study assesses the safety of switching from reference infliximab or infliximab-dyyb to Renflexis in patients with IBD identified from the VAHS database and […]Read More

Biotech

Jazz Collaborates with Redx Pharma to Develop Two Targeted Cancer

Shots: Redx to receive $10M as up front followed by another $10M in year two and will receive up to $400M as milestones along with royalties on sales of the therapies. The first milestone is payable following IND submission Following a successful IND submission, Jazz will be responsible for further development, manufacturing, regulatory activities, and […]Read More